Loading clinical trials...
Loading clinical trials...
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Northwestern
Evanston, Illinois, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Tufts Medical Center
Medford, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Virginia
Charlottesville, Virginia, United States
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
London Chest Hospital
London, United Kingdom
Start Date
March 30, 2026
Primary Completion Date
March 1, 2027
Completion Date
July 1, 2027
Last Updated
March 18, 2026
314
ESTIMATED participants
None - observational study
OTHER
Lead Sponsor
Christopher Kramer
Collaborators
NCT07344480
NCT07359690
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions